Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 1061-1067

  Shao, Qing ^a,b   Ren, Pengfei ^a,c   Li, Yang ^a   Peng, Bo ^a   Dai, Liping ^a,c   Lei, Ningjing ^a   Yao, Wu ^a,c   Zhao, Gang ^b   Li, Linggen ^b   Zhang, Jianying ^a,c  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

Autoantibody; Biomarker; GRP78; Hepatocellular carcinoma; Immunodiagnosis

Indexed keywords

ALPHA FETOPROTEIN ANTIBODY; AUTOANTIBODY; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 78 AUTOANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SERODIAGNOSIS; TISSUE MICROARRAY; WESTERN BLOTTING;

ADULT; AGED; AUTOANTIBODIES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEAT-SHOCK PROTEINS; HEPATITIS, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84864967298     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1515     Document Type: Article

References (47)

1. Gomaa AI, Khan SA, Toledano MB, Waked I and Taylor-Robinson SD: Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 14: 4300-4308, 2008.
2. Kudo M: Early detection and curative treatment of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol 3: S144-S148, 2005.
3. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003. (Pubitemid 37518510)
4. Lencioni R: Surveillance and early diagnosis of hepatocellular carcinoma. Dig Liver Dis 42: S223-S227, 2010.
5. Zhang BH, Yang BH and Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417-422, 2004.
6. Wong LL, Limm WM, Severino R and Wong LM: Improved survival with screening for hepatocellular carcinoma. Liver Transpl 6: 320-325, 2000. (Pubitemid 30317228)
7. Daniele B, Bencivenga A, Megna AS and Tinessa V: α-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127: S108-S112, 2004. (Pubitemid 39423377)
8. Tan EM: Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 108: 1411-1415, 2001.
9. Tan EM and Zhang JY: Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 222: 328-340, 2008. (Pubitemid 351430373)
10. Zhang JY and Tan EM: Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn 10: 321-328, 2010.
11. Zhang JY: Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma. Autoimmun Rev 6: 143-148, 2007.
12. Chen Y, Zhou YS, Qiu SM, Wang KJ, Liu SW, Peng XX, Li JF, et al: Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett 289: 32-39, 2010.
13. Lee AS: The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 26: 504-510, 2001.
14. Lee AS: GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67: 3496-3499, 2007.
15. Hendershot LM: The ER function BiP is a master regulator of ER function. Mt Sinai J Med 71: 289-297, 2004.
16. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, Morita M, et al: Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49: 55-62, 2005. (Pubitemid 40798093)
17. Fernandez PM, Tabbara SO, Jacobs LK, Manning FC, Tsangaris TN, Schwartz AM, Kennedy KA, et al: Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 59: 15-26, 2000. (Pubitemid 30153894)
18. Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF and Takano Y: Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol 39: 1042-1049, 2008.
19. Pootrakul L, Datar RH, Shi SR, Cai J, Hawes D, Groshen SG, Lee AS, et al: Expression of stress response protein GRP78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res 12: 5987-5993, 2006. (Pubitemid 44703758)
20. Luk JM, Lam CT, Siu AFM, Lam BY, Ng IOL, Hu MY, Che CM, et al: Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics 6: 1049-1057, 2006. (Pubitemid 43260229)
21. Dong DZ, Ni M, Li JZ, Xiong SG, Ye W, Virrey JJ, Mao CH, et al: Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 68: 498-505, 2008. (Pubitemid 351380077)
22. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, et al: Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 38: 1547-1552, 2007. (Pubitemid 47418966)
23. Su RJ, Li Z, Li HD, Song HJ, Bao CF, Wei J and Cheng LF: Grp78 promotes the invasion of hepatocellular carcinoma. BMC Cancer 10: 20, 2010.
24. Dong DZ, Stapleton C, Luo BQ, Xiong SG, Ye W, Zhang Y, Jhaveri N, et al: A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res 71: 2848-2857, 2011.
25. Katanasaka Y, Ishii T, Asai T, Naitou H, Maeda N, Koizumi F, Miyagawa S, et al: Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. Int J Cancer 127: 2685-2698, 2010.
26. Sugawara S, Takeda K, Lee A and Dennert G: Suppression of stress protein GRP78 induction in tumor B/C10ME eliminates resistance to cell mediated cytotoxicity. Cancer Res 53: 6001-6005, 1993. (Pubitemid 24006173)
27. Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, BS JA, Wu CH, et al: Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol 17: 603-612, 2010.
28. Berger CL, Dong ZM, Hanlon D, Bisaccia E and Edelson RL: A lymphocyte cell surface heat shock protein homologous to the endoplasmic reticulum chaperone, immunoglobulin heavy chain binding protein BIP. Int J Cancer 71: 1077-1085, 1997. (Pubitemid 27252893)
29. Shin BK, Wang H, Yim AM, Naour FL, Brichory F, Jang JH, Zhao R, et al: Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 278: 7607-7616, 2003. (Pubitemid 36800769)
30. Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W and Pasqualini R: Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6: 275-284, 2004. (Pubitemid 39222040)
31. Mintz PJ, Kim J, Do KA, Wang XM, Zinner RG, Cristofanilli M, Arap MA, et al: Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21: 57-63, 2003. (Pubitemid 36055828)
32. Gonzalez-Gronow M, Cuchacovich M, Llanos C, Urzua C, Gawdi G and Pizzo SV: Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res 66: 11424-11431, 2006. (Pubitemid 46009974)
33. Tsunemi S, Nakanishi T, Fujita Y, Bouras G, Miyamoto Y, MiyamotoI A, Nomura E, et al: Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer. Oncol Rep 23: 949-956, 2010.
34. Johnson PJ, Leung N, Cheng P, Welby C, Leung WT, Lau WY, Yu S and Ho S: 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer 75: 236-240, 1997.
35. Gordis L (ed): Assessing the validity and reliability of diagnostic and screening tests. In: Epidemiology. 2nd edition. W.B. Saunders Company, Philadelphia, PA, pp63-81, 2000.
36. Kaufman RJ: Orchestrating the unfolded protein response in health and disease. J Clin Invest 110: 1389-1398, 2002.
37. Ni M and Lee AS: ER chaperones in mammalian development and human diseases. FEBS Lett 581: 3641-3651, 2007. (Pubitemid 47082516)
38. Pfaffenbach KT and Lee AS: The critical role of GRP78 in physiologic and pathologic stress. Curr Opin Cell Biol 23: 150-156, 2011.
39. Lim SO, Park SG, Yoo JH, Park YM, Kim HJ, Jang KT, Cho JW, et al: Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol 11: 2072-2079, 2005. (Pubitemid 40542649)
40. Misra UK, Deedwania R and Pizzo SV: Binding of activated α2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK. J Biol Chem 280: 26278-26286, 2005. (Pubitemid 41022225)
41. Shani G, Fischer WH, Justice NJ, Kelber JA, Vale W and Gray PC: GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor β signaling and enhance cell growth. Mol Cell Biol 28: 666-677, 2008.
42. Al-Hashimi AA, Caldwell J, Gonzalez-Gronow M, Pizzo SV, Aboumrad D, Pozza L, Al-Bayati H, et al: Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. J Biol Chem 285: 28912-28923, 2010.
43. Kelber JA, Panopoulos AD, Shani G, Booker EC, Belmonte JC, Vale WW and Gray PC: Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 28: 2324-2336, 2009.
44. Ni M, Zhang Y and Lee AS: Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 434: 181-188, 2011.
45. Misra UK and Pizzo AV: Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. Cancer Biol Ther 9: 1-11, 2010.
46. Misra UK, Mowery Y, Kaczowka S and Pizzo SV: Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis. Mol Cancer Ther 8: 1350-1362, 2009.
47. Backes C, Ludwig N, Leidinger P, Harz C, Hoffmann J, Keller A, Meese E, et al: Immunogenicity of autoantigens. BMC Genomics 12: 340, 2011.